Insulet Corporation has partnered with Calm to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. The collaboration introduces The Mind in Range Collection, a set of tailored mindfulness tools available at no cost, designed to address the mental health challenges associated with diabetes management. This initiative marks Calm’s first integrated content partnership with a MedTech company.

The Mind in Range Collection is available on the Calm app and website. It features a sleep story narrated by fashion model and Omnipod user Lila Moss, a series of guided meditations to manage stress, and a breathing exercise for quick resets. The content aims to reduce the cognitive burden and emotional stress often experienced by those managing diabetes.

Global research from Insulet highlights the need for such holistic support. The data reveals that 66% of people with diabetes and 46% of caregivers report poor-quality sleep driven by diabetes-related stress. Additionally, 62% of people with type 1 diabetes and 60% with type 2 diabetes expressed a desire for support that includes mental health and mindfulness.

Impact of Mindfulness on Diabetes Care

Studies indicate that mindfulness-based stress reduction can meaningfully reduce stress for people with diabetes over time. Among those already using mindfulness tools, 39% reported less stress, while 33% experienced less anxiety and fewer sleep problems.

Manoj Raghunandanan, Chief Growth Officer at Insulet, emphasized that living with diabetes requires constant decisions that can create stress and anxiety. He noted that nearly 80% of people living with diabetes suffer burnout from the emotional strain of daily management. Partnering with Calm allows Insulet to expand support beyond physical outcomes to include the emotional dimension of diabetes care.

Dr. Chris Mosunic, Chief Clinical Officer at Calm, stated that mindfulness plays a powerful role in improving quality of life for people living with diabetes. By combining Calm’s expertise with Insulet’s leadership in diabetes technology, the partnership aims to deliver tools that reduce cognitive burden and relieve emotional stress.

The initiative will roll out globally, with bespoke content promoted across Omnipod and Calm channels throughout the year. Users can access the free resources, including the guided meditations and Lila Moss’s sleep story, via the Omnipod × Calm page.

Truist Securities analyst Richard Newitter has maintained a Buy rating on Insulet (NASDAQ: PODD) while lowering the price target to $210 from $219. The adjustment reflects a revised valuation outlook for the medical device company.

Rating and Target Details

The analyst's decision to retain the Buy rating suggests continued confidence in Insulet's business fundamentals despite the reduced price objective. The new target of $210 represents a decrease from the prior estimate of $219.